- Report
- February 2026
- 150 Pages
Canada
From €4320EUR$4,850USD£3,771GBP
- Report
- September 2024
- 150 Pages
Global
From €4320EUR$4,850USD£3,771GBP
- Report
- June 2025
- 80 Pages
From €3073EUR$3,450USD£2,683GBP
- Report
- November 2023
- 85 Pages
Global
From €2628EUR$2,950USD£2,294GBP
- Report
- November 2023
- 88 Pages
Asia Pacific
From €3073EUR$3,450USD£2,683GBP
- Report
- November 2023
- 110 Pages
Global
From €4008EUR$4,500USD£3,499GBP
- Webinar
- May 2023
- 90 Minutes
Global
From €159EUR$179USD£139GBP
- Webinar
- January 2023
- 120 Minutes
United States
- Training
- 120 Minutes
Global
- Book
- November 2022
- 600 Pages
- Report
- February 2024
- 138 Pages
Global
From €3500EUR$4,209USD£3,162GBP
- Book
- October 2023
Global
The Epidemic market within the context of Biotechnology is a sector of the industry that focuses on the development of products and services to address the challenges posed by the spread of infectious diseases. This includes the development of vaccines, diagnostics, treatments, and other preventive measures. It also includes the development of technologies to monitor and track the spread of disease, as well as the development of public health policies and strategies to reduce the impact of epidemics.
The Epidemic market is a rapidly growing sector of the biotechnology industry, with many companies investing in research and development to create new products and services. Companies in this market include Gilead Sciences, Moderna, Johnson & Johnson, Novavax, Inovio Pharmaceuticals, and Regeneron Pharmaceuticals. Show Less Read more
